DE3913438A1 - Verfahren zum herstellen einer immunitaetsgedaechtniszellsuspension - Google Patents
Verfahren zum herstellen einer immunitaetsgedaechtniszellsuspensionInfo
- Publication number
- DE3913438A1 DE3913438A1 DE3913438A DE3913438A DE3913438A1 DE 3913438 A1 DE3913438 A1 DE 3913438A1 DE 3913438 A DE3913438 A DE 3913438A DE 3913438 A DE3913438 A DE 3913438A DE 3913438 A1 DE3913438 A1 DE 3913438A1
- Authority
- DE
- Germany
- Prior art keywords
- cells
- immunity
- cell suspension
- immunity memory
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000036039 immunity Effects 0.000 title claims abstract description 150
- 230000015654 memory Effects 0.000 title claims abstract description 148
- 239000006285 cell suspension Substances 0.000 title claims description 123
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 210000004027 cell Anatomy 0.000 claims abstract description 286
- 239000000427 antigen Substances 0.000 claims abstract description 75
- 102000036639 antigens Human genes 0.000 claims abstract description 75
- 108091007433 antigens Proteins 0.000 claims abstract description 75
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 29
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 24
- 244000052769 pathogen Species 0.000 claims abstract description 18
- 210000002966 serum Anatomy 0.000 claims abstract description 18
- 230000000295 complement effect Effects 0.000 claims abstract description 7
- 230000002085 persistent effect Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 18
- 238000001042 affinity chromatography Methods 0.000 claims description 16
- 239000004677 Nylon Substances 0.000 claims description 12
- 229920001778 nylon Polymers 0.000 claims description 12
- 239000011491 glass wool Substances 0.000 claims description 11
- 230000005855 radiation Effects 0.000 claims description 10
- 239000003463 adsorbent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- 230000006054 immunological memory Effects 0.000 claims description 6
- 230000002285 radioactive effect Effects 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 3
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000000725 suspension Substances 0.000 abstract description 21
- 201000011510 cancer Diseases 0.000 abstract description 10
- 208000035473 Communicable disease Diseases 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 6
- 241000894007 species Species 0.000 abstract description 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 23
- 239000002609 medium Substances 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 210000004698 lymphocyte Anatomy 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 238000005119 centrifugation Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 239000012981 Hank's balanced salt solution Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 7
- 239000012894 fetal calf serum Substances 0.000 description 7
- 238000011835 investigation Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 210000001840 diploid cell Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000011278 mitosis Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000010959 steel Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000725630 Ectromelia virus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000711408 Murine respirovirus Species 0.000 description 2
- 101100438957 Mus musculus Cd8a gene Proteins 0.000 description 2
- 101100438963 Mus musculus Cd8b gene Proteins 0.000 description 2
- 101000934342 Mus musculus T-cell surface glycoprotein CD5 Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 238000003320 cell separation method Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000004304 subcutaneous tissue Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000009485 HLA-D Antigens Human genes 0.000 description 1
- 108010048896 HLA-D Antigens Proteins 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
- C12N5/0087—Purging against subsets of blood cells, e.g. purging alloreactive T cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63300726A JP2639834B2 (ja) | 1988-11-30 | 1988-11-30 | 免疫記憶細胞懸濁液およびその調製方法 |
| CA000596787A CA1333887C (en) | 1988-11-30 | 1989-04-14 | Immunity memory cell suspension and method of preparing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3913438A1 true DE3913438A1 (de) | 1990-10-25 |
Family
ID=25672621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3913438A Granted DE3913438A1 (de) | 1988-11-30 | 1989-04-24 | Verfahren zum herstellen einer immunitaetsgedaechtniszellsuspension |
Country Status (7)
| Country | Link |
|---|---|
| JP (1) | JP2639834B2 (enrdf_load_stackoverflow) |
| AU (1) | AU603950B1 (enrdf_load_stackoverflow) |
| CA (1) | CA1333887C (enrdf_load_stackoverflow) |
| CH (1) | CH678337A5 (enrdf_load_stackoverflow) |
| DE (1) | DE3913438A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2646778B1 (enrdf_load_stackoverflow) |
| GB (1) | GB2230790B (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925405A1 (de) * | 1999-06-02 | 2000-12-07 | Wilfried P Bieger | Verfahren zum Nachweis von spezifisch antigenreaktiven Lymphozyten sowie ein Nachweis-Kit zur Durchführung dieses Verfahrens |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1340565C (en) | 1989-06-29 | 1999-05-25 | Thomas B. Okarma | Device and process for cell capture and recovery |
| US6143508A (en) * | 1989-06-29 | 2000-11-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Device and process for cell capture and recovery |
| SE467498B (sv) * | 1990-11-20 | 1992-07-27 | Vera Stejskal | Foerfarande foer in vitro analys av kvicksilverallergier |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0077571A3 (en) * | 1981-10-19 | 1983-10-12 | Ajinomoto Co., Inc. | Process for producing a lymphokine |
| WO1988007077A1 (en) * | 1987-03-11 | 1988-09-22 | The Children's Hospital, Incorporated | Method for the generation of antigen-specific t cell lines and therapeutic use thereof |
| JPS63300727A (ja) * | 1987-05-29 | 1988-12-07 | 古形 勝 | 健康タワシ |
-
1988
- 1988-11-30 JP JP63300726A patent/JP2639834B2/ja not_active Expired - Lifetime
-
1989
- 1989-04-12 GB GB8908241A patent/GB2230790B/en not_active Expired - Fee Related
- 1989-04-12 AU AU32747/89A patent/AU603950B1/en not_active Ceased
- 1989-04-14 CA CA000596787A patent/CA1333887C/en not_active Expired - Fee Related
- 1989-04-24 DE DE3913438A patent/DE3913438A1/de active Granted
- 1989-05-11 FR FR898906179A patent/FR2646778B1/fr not_active Expired - Fee Related
- 1989-05-17 CH CH1833/89A patent/CH678337A5/fr not_active IP Right Cessation
Non-Patent Citations (1)
| Title |
|---|
| NICHTS ERMITTELT * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925405A1 (de) * | 1999-06-02 | 2000-12-07 | Wilfried P Bieger | Verfahren zum Nachweis von spezifisch antigenreaktiven Lymphozyten sowie ein Nachweis-Kit zur Durchführung dieses Verfahrens |
| DE19925405C2 (de) * | 1999-06-02 | 2003-02-13 | Bieger Wilfried W | Verfahren zum Nachweis von spezifisch antigenreaktiven Lymphozyten sowie ein Nachweis-Kit zur Durchführung dieses Verfahrens |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH02150274A (ja) | 1990-06-08 |
| CA1333887C (en) | 1995-01-10 |
| FR2646778A1 (fr) | 1990-11-16 |
| FR2646778B1 (fr) | 1991-08-23 |
| GB2230790A (en) | 1990-10-31 |
| GB2230790B (en) | 1993-04-21 |
| GB8908241D0 (en) | 1989-05-24 |
| CH678337A5 (enrdf_load_stackoverflow) | 1991-08-30 |
| JP2639834B2 (ja) | 1997-08-13 |
| AU603950B1 (en) | 1990-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3227262C3 (de) | Verfahren zur Herstellung von menschlichem Tumor-Nekrose-Faktor und menschlicher Tumor-Nekrose-Faktor | |
| DE69033083T2 (de) | Verfahren zur Fixierung und Rückgewinnung von Zellen | |
| DE2651685C2 (de) | Züchtung von Keratinozyten | |
| DE3152113C2 (de) | Verfahren zum Bestimmen der Stoffwechselumwandlung bestimmter Chemikalien und Wirkstoffe | |
| DE4412794A1 (de) | Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens | |
| EP0584715B1 (de) | Verfahren zur Isolierung und Kultivierung von transformierten Zellen sowie Verwendung dieser Zellen zur Herstellung individuumsspezifischer Antikörper | |
| Fox | Cytological estimation of proliferating donor cells during graft-versus-host disease in F1 hybrid mice injected with parental spleen cells | |
| DD210708A5 (de) | Verfahren zur herstellung permanenter tierischer und humaner zellinien | |
| DE1195905B (de) | Verfahren zum Abtrennen der Zellwaende von Mycobacterium phlei | |
| DE2645993C2 (enrdf_load_stackoverflow) | ||
| DE2555169C2 (enrdf_load_stackoverflow) | ||
| DE69329340T2 (de) | Aufbewahren von stammzellen | |
| DE3913438A1 (de) | Verfahren zum herstellen einer immunitaetsgedaechtniszellsuspension | |
| DE69020157T2 (de) | Verstärkte aktivierung von lak-zellen durch behandlung menschlicher peripherer mononuklearer blutzellen mit aminosäuren. | |
| DE2352662A1 (de) | Verfahren zur herstellung eines uebertragungsfaktors | |
| DE3424640A1 (de) | Verfahren zur gewinnung und/oder bestimmung von humanspezifischem interferon im blut | |
| CH650154A5 (de) | Wasserloesliche, biologisch aktive fraktion aus dem interzellularen medium des knochenmarks, verfahren zu deren gewinnung und diese enthaltende pharmazeutische zubereitung. | |
| DE69016432T2 (de) | Verfahren zur herstellung menschlicher adhärenter lymphokin-aktivierter killerzellen (alak). | |
| DE1617605C3 (de) | Verfahren zum Herstellen eines Pertussis-Antigens | |
| DE3239863A1 (de) | Verfahren zur herstellung von subkultivierbaren lymphokin-bildenden human-t-zellenhybridomas | |
| DE602004013291T2 (de) | Dendritische zelle mit alpha-glycosylceramid-derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen | |
| DE2016274A1 (enrdf_load_stackoverflow) | ||
| DD283330A5 (de) | Zepareth-herstellungsverfahren aus selektierten zellinien begrenzter vermehrungspotenz (finit lines) | |
| DE10047272A1 (de) | Verfahren zur Fusion von dendritischen Zellen mit erkrankten Gewebezellen, insbesondere Tumorzellen und Medien für solche Verfahren | |
| DE69433472T2 (de) | Recognin-vakzine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OP8 | Request for examination as to paragraph 44 patent law | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |